Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1467-1472

  Kawaoka, Tomokazu ^a,b   Takahashi, Shoichi ^b   Takaki, Shintaro ^b   Hiramatsu, Akira ^b   Waki, Koji ^b   Hiraga, Nobuhiko ^a,b   Miki, Daiki ^a,b   Tsuge, Masataka ^a   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Aikata, Hiroshi ^a   Ochi, Hidenori ^a,b   Onoe, Takashi ^a   Tashiro, Hirotaka ^a   Ohdan, Hideki ^a   Chayama, Kazuaki ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

Core; Hepatitis C virus; Interferon sensitivity determining region; Interleukin 28B; Liver transplantation

Indexed keywords

CYCLOSPORIN; INTERLEUKIN 28B; NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TACROLIMUS; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LONG TERM CARE; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECURRENT INFECTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

EID: 84865399454     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07129.x     Document Type: Article

References (39)

1. Szabo E, Lotz G, Paska C, Kiss A, Schaff Z. Viral hepatitis: new data on hepatitis C infection. Pathol. Oncol. Res. 2003; 9: 215-21.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-71.
3. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-4.
4. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
5. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-9.
6. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
7. Rauch A, Kutalik Z, Descombes P etal. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138: 1338-45, 45 e1-7.
8. Fukuhara T, Taketomi A, Motomura T etal. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-85, 85 e1-3.
9. Sanchez-Fueyo A, Restrepo JC, Quinto L etal. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56-63.
10. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-96.
11. Berenguer M, Prieto M, San Juan F etal. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-10.
12. Feray C, Caccamo L, Alexander GJ etal. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619-25.
13. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003; 9: S28-34.
14. Prieto M, Berenguer M, Rayon JM etal. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250-6.
15. Velidedeoglu E, Mange KC, Frank A etal. Factors differentially correlated with the outcome of liver transplantation in HCV+ and HCV- recipients. Transplantation 2004; 77: 1834-42.
16. Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J. Viral Hepat. 2000; 7: 87-92.
17. Thomas RM, Brems JJ, Guzman-Hartman G, Yong S, Cavaliere P, Van Thiel DH. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl. 2003; 9: 905-15.
18. Ueda Y, Takada Y, Haga H etal. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008; 85: 855-62.
19. Sugawara Y, Makuuchi M, Matsui Y etal. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-11.
20. Sugawara Y, Makuuchi M. Living donor liver transplantation to patients with hepatitis C virus cirrhosis. World J. Gastroenterol. 2006; 12: 4461-5.
21. Roche B, Sebagh M, Canfora ML etal. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl. 2008; 14: 1766-77.
22. Lodato F, Berardi S, Gramenzi A etal. Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation. Aliment. Pharmacol. Ther. 2008; 28: 450-7.
23. Dinges S, Morard I, Heim M etal. Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation. Transpl. Infect. Dis. 2009; 11: 33-9.
24. Saab S, Oh MK, Ibrahim AB etal. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl. 2007; 13: 1032-8.
25. Kawaoka T, Hiraga N, Takahashi S etal. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus. Scand. J. Gastroenterol. 2010; 45: 1488-96.
26. Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl. Int. 2009; 6: 580-588.
27. Ueda Y, Takada Y, Marusawa H, Egawa H, Uemoto S, Chiba T. Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation. Transplantation 2010; 6: 661-5.
28. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 2001; 46: 471-7.
29. Suzuki A, Yamada R, Chang X etal. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 2003; 34: 395-402.
30. Kitamura S, Tsuge M, Hatakeyama T etal. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy. Antivir. Ther. 2010; 15: 1087-97.
31. Mori N, Imamura M, Kawakami Y etal. Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. J. Med. Virol. 2009; 81: 640-9.
32. Akuta N, Suzuki F, Kawamura Y etal. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 2007; 79: 1686-95.
33. Akuta N, Suzuki F, Kawamura Y etal. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J. Hepatol. 2007; 46: 403-10.
34. Lange CM, Moradpour D, Doehring A etal. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J. Hepatol. 2011; 55: 322-7.
35. Eurich D, Boas-Knoop S, Ruehl M etal. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transpl. 2011; 17: 289-98.
36. Coto-Llerena M, Perez-Del-Pulgar S, Crespo G etal. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am. J. Transplant. 2011; 11: 1051-7.
37. Charlton MR, Thompson A, Veldt BJ etal. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology 2011; 53: 317-24.
38. Hiraga N, Abe H, Imamura M etal. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology 2011; 3: 764-71.
39. Miller DM, Klucher KM, Freeman JA, Hausman DF, Fontana D, Williams DE. Interferon lambda as a potential new therapeutic for hepatitis C. Ann. N. Y. Acad. Sci. 2009; 1182: 80-7.